Nina Wallander - CellaVision VP HR
| CEVI Stock | SEK 221.50 7.00 3.26% |
Insider
Nina Wallander is VP HR of CellaVision AB
| Age | 49 |
| Phone | 46 4 64 60 16 00 |
| Web | https://www.cellavision.com |
CellaVision Management Efficiency
The company has return on total asset (ROA) of 0.1152 % which means that it generated a profit of $0.1152 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1997 %, meaning that it generated $0.1997 on every $100 dollars invested by stockholders. CellaVision's management efficiency ratios could be used to measure how well CellaVision manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Troels Dalsgaard | GomSpace Group AB | 37 | |
| Bjrn Frendus | BioInvent International AB | 50 | |
| Emanuel Bjrne | Hansa Biopharma AB | 50 | |
| Lani Morvan | Zealand Pharma AS | N/A | |
| Sylvie Ryckebusch | BioInvent International AB | N/A | |
| Ingrid Teige | BioInvent International AB | N/A | |
| Christina Bredal | Zealand Pharma AS | 38 | |
| Thomas Pfister | GomSpace Group AB | 47 | |
| Hanne Bak | Zealand Pharma AS | 70 | |
| MBA MSc | Orphazyme AS | 53 | |
| Katja Margell | Hansa Biopharma AB | N/A | |
| Danilo Verge | Zealand Pharma AS | N/A | |
| Cecilia Hofvander | BioInvent International AB | 56 | |
| Brge Witthft | GomSpace Group AB | 71 | |
| Ivan Moller | Zealand Pharma AS | 51 | |
| Mads Kronborg | Zealand Pharma AS | N/A | |
| RGN MSc | BioInvent International AB | N/A | |
| Henriette Wennicke | Zealand Pharma AS | N/A | |
| Anne Lanner | Hansa Biopharma AB | 54 | |
| Stefan MBA | BioInvent International AB | 60 | |
| Sren MSc | Hansa Biopharma AB | 58 | |
Management Performance
CellaVision AB Leadership Team
Elected by the shareholders, the CellaVision's board of directors comprises two types of representatives: CellaVision inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CellaVision. The board's role is to monitor CellaVision's management team and ensure that shareholders' interests are well served. CellaVision's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CellaVision's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Yve Thorenburg, Acting Sales | ||
| Julien Veyssy, Managing Diagnostics | ||
| Magnus Blixt, Ex Officer | ||
| Urban Strindlov, VP Sales | ||
| Maths hc, Founder Director | ||
| Simon Ostergaard, CEO Pres | ||
| Peter Wilson, Vice President Global Marketing | ||
| Nina Wallander, VP HR |
CellaVision Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CellaVision a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.2 | |||
| Return On Asset | 0.12 | |||
| Profit Margin | 0.19 % | |||
| Operating Margin | 0.25 % | |||
| Current Valuation | 6.21 B | |||
| Shares Outstanding | 23.85 M | |||
| Shares Owned By Insiders | 38.15 % | |||
| Shares Owned By Institutions | 43.00 % | |||
| Price To Earning | 90.85 X | |||
| Price To Book | 10.18 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for CellaVision Stock Analysis
When running CellaVision's price analysis, check to measure CellaVision's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CellaVision is operating at the current time. Most of CellaVision's value examination focuses on studying past and present price action to predict the probability of CellaVision's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CellaVision's price. Additionally, you may evaluate how the addition of CellaVision to your portfolios can decrease your overall portfolio volatility.